---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-040104"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:50:33.630122+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Femasys gets FDA IDE approval for FemBloc final trial phase, secures $12M financing

## Summary
- FDA IDE approval to continue enrollment in Part B of FINALE pivotal trial for FemBloc non-surgical permanent birth control.
- $12M senior secured convertible notes issued with potential total proceeds of $58M if all warrants exercised.
- Notes bear 8.5% interest, 10-year maturity, convertible at $0.73/share (15% premium to last close).
- Warrants issued at exercise prices of $0.81, $0.92, and $1.10 per share, each for 16.4M shares.
- Proceeds to refinance debt and advance commercialization of fertility and birth control portfolio.

## SEC filing metadata
- accession: 0001140361-25-040104
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036125040104/0001140361-25-040104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036125040104/ef20058162_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-040104
- JSON: https://secwatch.observer/filing/0001140361-25-040104.json
- Plain text: https://secwatch.observer/filing/0001140361-25-040104.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.